[1] [3] The Summary of Product Characteristics does not include sleep disturbances, insomnia, or related terms among the documented adverse reactions from clinical trials or post-marketing surveillance data
Some patients report better tolerance with certain compounding pharmacy formulations, though this has not been systematically studied
For the broader picture of which peptides already have FDA approval, see our FDA Approved Peptides List 2026
J Neuroophthalmol 39(1):8293 De Simone R et al (2020) Headache in idiopathic intracranial hypertension A
It activates 3-adrenergic receptors in adipose tissue and stimulates fatty acid oxidation
Retatrutide powder should be stored at 20C in sealed amber vials, away from light and moisture, exclusively within regulated clinical trial or research pharmacy settings, as it is not a licensed medicine in the UK